Aethlon Medical Announces Independent Data Safety Monitoring Board Completes Its Safety Review For AEMD-2022-06; Finds No Safety Concerns; Recommends Third And Final Cohort

Aethlon Medical, Inc. (Nasdaq: AEMD) announced that the independent Data Safety Monitoring Board (DSMB) has completed its safety review for the clinical trial AEMD-2022-06. The DSMB found no safety concerns regarding the Hemopurifier device and has recommended advancing to the third and final cohort of the trial.